Literature DB >> 15880746

On ubiquitin ligases and cancer.

Jacques S Beckmann1, Fabienne Maurer, Mauro Delorenzi, Laurent Falquet.   

Abstract

Protein kinase genes account for almost 10% of all currently known cancer genes, highlighting the role of signal transduction in oncogenesis. A reexamination of the literature and available databases shows that E3 ubiquitin ligases are also key mediators of tumorigenesis. Altogether kinase and E3 genes represent more than 15% of the known cancer genes, underlining the importance of phosphorylation and ubiquitylation signaling pathways in cancer formation. Considering the recent literature reporting correlations between alterations in ubiquitylation processes and oncogenesis, this percentage is likely to increase even further in the future. Finally, E3 genes could serve as baits for the identification of additional cancer genes (e.g. their interacting partners). In contrast, deubiquitinases, like phosphatases, are not overrepresented among cancer genes. The same holds for E1 and E2 genes. Thus, kinase and E3 genes represent primary targets as cancer susceptibility genes for mutation screening and for the design of novel therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880746     DOI: 10.1002/humu.20175

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  2 in total

1.  Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signalling, anti-apoptotic protein expression, and drug resistance in breast cancer cells.

Authors:  Tyler M MacDonald; Lynn N Thomas; Emily Daze; Paola Marignani; Penelope J Barnes; Catherine Kl Too
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

2.  Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling.

Authors:  Wei Li; Mario H Bengtson; Axel Ulbrich; Akio Matsuda; Venkateshwar A Reddy; Anthony Orth; Sumit K Chanda; Serge Batalov; Claudio A P Joazeiro
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.